By May 2019

Qurgen announced that the Company had successfully completed its Series A financing with 12 million USD that will be mainly used for the FDA IND application and clinical studies of SON-DP, a first-in-human and first-in-class transcription factor anti-cancer protein drug that leads to a breakthrough cell-conversion cancer therapy.